Home

Kyle Jenne

CIK 1791857 · EVP, Chf GL Pdt Str Ofcr · last filed 2026-04-17

Kyle Jenne is an EVP, Chf GL Pdt Str Ofcr who has filed 17 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for IONS, was dated Apr 17, 2026. Across all open-market trades the lifetime net is −$3.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.4M across reported positions. 13 SEC filings were submitted jointly with IONIS PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.35M

Companies

2

Total Filings

17

Lifetime Open-Market Net

-$3.44M

Filer Profile

Reported Address
C/O AKCEA THERAPEUTICS, INC.
22 BOSTON WHARF ROAD, 9TH FLOOR
BOSTON, MA 02210
Related Filers
IONIS PHARMACEUTICALS INC — 13 joint filings, latest 2026-04-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IONS EVP, Chf GL Pdt Str Ofcr 28,615 $47.25 $1.35M -$3.42M 8 2026-04-17
AKCEA THERAPEUTICS, INC. (AKCA) Delisted Chief Commercial Officer 0 — — -$22.2K 5 2020-10-13

Recent Filings

17 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-04-17 IONS Mixed +7,324 -$368.5K EDGAR
2026-04-16 IONS Notice (144) −4,902 -$369.6K EDGAR
2026-03-11 IONS Mixed — -$1.16M EDGAR
2026-03-10 IONS Notice (144) −58,253 -$4.40M EDGAR
2026-01-20 IONS Mixed +5,190 -$138.5K EDGAR
2026-01-16 IONS Notice (144) −1,823 -$139.0K EDGAR
2026-01-06 IONS Grant (A) — $0 EDGAR
2025-04-17 IONS Mixed +9,210 -$85.5K EDGAR
2025-04-16 IONS Notice (144) −3,016 -$85.5K EDGAR
2025-01-17 IONS Grant (A) — $0 EDGAR
Showing 1–10 of 17
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.